Back to News
Market Impact: 0.25

Peter Lynch Detailed Fundamental Analysis

BDXNDAQ
Company FundamentalsAnalyst InsightsCorporate EarningsHealthcare & BiotechInvestor Sentiment & Positioning
Peter Lynch Detailed Fundamental Analysis

Validea's guru fundamental report indicates Becton Dickinson (BDX), a large-cap medical equipment stock, rates highest using the Peter Lynch P/E/Growth Investor model, achieving a 50% score. This rating, however, falls below the 80% threshold typically signaling investment interest. The analysis reveals a mixed fundamental profile for BDX, passing criteria such as P/E/Growth Ratio and Total Debt/Equity, but failing on Sales and P/E Ratio and EPS Growth Rate.

Analysis

According to a fundamental report by Validea, Becton Dickinson and Co. (BDX) presents a mixed profile when evaluated against the Peter Lynch-based P/E/Growth Investor model. The company received a score of 50%, which falls significantly short of the 80% threshold that typically signals investment interest from this specific strategy. The analysis highlights several fundamental strengths, as BDX passed criteria for its P/E/Growth Ratio, Inventory to Sales, and Total Debt/Equity Ratio, indicating a potentially reasonable valuation relative to growth, efficient inventory management, and a strong balance sheet. However, these positives are offset by notable weaknesses, with the company failing on its Sales to P/E Ratio and, critically, its EPS Growth Rate. Furthermore, metrics for Free Cash Flow and Net Cash Position were deemed neutral. This combination suggests that while BDX exhibits financial stability and some favorable valuation aspects, its lack of robust earnings growth and a less attractive sales-based valuation prevent it from being a compelling candidate under this growth-at-a-reasonable-price framework.

AllMind AI Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request a Demo